Ibrutinib, iBrentuximab, iBlinatumomab kunye ne-Idelalisib
I-American Society of Hematology (ASH) yinkcubeko enkulu yehlabathi echaphazelekayo ebangela izizathu kunye nokunyanga kweengxaki zegazi. Unyaka wonke, i-best and brightest emhlabeni jikelele iza ku-ASH.
Kulo nyaka, bekukho iseshoni malunga nemibandela emitsha ye-FDA evunyiweyo yeemeko ze-hematologic. Kwakubanjwe kuba oogqirha babefuna ulwazi oluninzi malunga nokuvunyelwa kwe-FDA kwangoku.
Abathengi babuyekeze uluhlu lweenkcukacha malunga namachiza amasha, kuquka ibrutinib (Imbruvica), kunye ne-idelalisib (iZydelig).
Kwabaninzi, intlanganiso yeDisemba ye-ASH isebenza njengomboniso kuyo yonke inkqubela eyenziwe kunyaka owedlule kwi-hematology kunye ne-oncology. Nazi ezinye zezinto abantu abazithetha ngazo.
Ibrutinib (Imbruvica)
Iiprotheni ezahlukeneyo okanye izakhiwo ezinjenge-enzymes, zidlala indima ekutshaleni iselenzana-inkqubo apho iiseli "ziphulaphule" kwaye ziphendule iimpawu zamachiza. I-Tyrosine Kinase (BTK) yaseBruton, i-enzyme ebambe indima ebalulekileyo ekuphuhliseni i-cell cell, ngumzekelo wendlela enzyme elawula ukutyhilwa kweseli. Ibrutinib yi-molecule encinci evimbela i-enzyme BTK.
Ngokuvalela le enzyme, ibrutinib iphazamisa indlela yokubonisa ukuba ezinye iiseli zomhlaza zithembele. Ngokusekelwe kwimpumelelo ngoku, i-FDA ikhethe ibrutinib njengonyango lophuhliso, inendima ekuphatheni izi zigulane ezilandelayo:
- Izigulane ezingapheliyo ze-lymphocytic leukemia (CLL) ezifumana ubuncinane unyango lokuqala
- Izigulane ze-lymphocytic leukemia (CLL) ezine-17p deletion
- Izigulane ze-Mantle cell lymphoma (MCL) ezifumana ubuncinane unyango lokuqala
Ibrutinib yipilisi ethathwa kanye ngosuku kwaye iyakunyamezela kakuhle. Ukusetyenziswa kwe-ejenti kuphandwa kwakhona kunyango lwezinye i-cancer, zombini yodwa kunye kunye neendlela ezahlukeneyo zokwelapha.
Idelalisib (Zydelig)
I-Idelalisib i-FDA-evunyelwe abantu abane -leyemia ye-lymphocytic (LLL) engapheliyo , ephindaphindiweyo isallicular B-cell engeyona i-Hodgkin lymphoma (FL), kwaye ibuyele kwakhona i-lymphocytic lymphoma encinci (SLL, olunye uhlobo lwe-non-Hodgkin lymphoma).
Ukuvunyelwa kusekelwe kwiziphumo zolu vavanyo kwizigulane ezingama-220 ezineCLL, kwakhona apho kwakucwangciswe khona i-chemotherapy eqhelekileyo. I-regimen yayiyi-idelalisib + rituximab okanye i- placebo + rituximab. Ulingo lubonisa ukunciphisa u-82% engozini yokuqhubela umdlavuza kunye ne-idelalisib, ngoko bawayeka ngokukhawuleza, ukuvumela i-placebo + i- rituximab izigulana zikwazi konke malunga ne-idelalisib kwaye ziwanike izilwanyana ezintsha. Zonke izigulane kwiqela lendawo ye-rituximab + ye-placebo zaqala ukufumana i-idelalisib.
I-Brentuximab vedotin (Adcetris)
Eli arhente ngumjovo we-infusion. I-Brentuximab vedotin inendlela yokwenza umdla. Ingqungquthela eyenziwa yi-antibody - idibaniswe ne-arhente enceda ukubulala amangqamuzana omhlaza emva kokufikelela ekujoliswe kuwo. Ijoliswe kwiprotheyini ebizwa ngokuba yi-CD30, ekhoyo kwi-classic Hodgkin lymphoma (HL) kunye nakwi-systemic iplastiki enkulu yeli lymphoma (i-SCLCL).
Ucwaningo oluxutyushwa kwi-ASH lwaluyinto yokuqala kwi-lymphoma ukubonisa ukuba ukongezwa kwesilwanyana emva kokutshintshwa kunokwenza ngcono iziphumo zesigulane.
Kwisilingo se-AETHERA, malunga ne-63% yezigulane eziphezulu zengozi ye-lymphoma eziye zanyangwa neziyobisi zineziphumo zokusinda kwenyanga engama-24 zihamba ngokungafaniyo kunye ne-51% yezigulane ezithe zafumana indawo ye-placebo.
IBlinatumomab (iBlincyto)
Esi sidakamizwa sisona semithi yokuqala ye-BITE (i-T ethile ye-Cell Engager) eya kuvunywa. Luye wabonisa umsebenzi obalulekileyo kwi-B-cell acute lucphocytic leukemia (ZONKE) izigulane ezinesifo esincinci se-residu emva kokunyangwa kweyeza , ngokutsho kwabaphandi base-ASH. I-Blinatumomab yahlutha iiseli zesifo somhlaza ukusuka kwi-78% yezigulane eziphathekayo ezingama-112.
Ngokutsho kweNational Cancer Institute, i-blinatumomab yintsholongwane eyenziwa yinkqubo yokukhusela i-immune system kwaye ihambe emva komhlaza ngemisebenzi ye-antineoplastic.
I-FDA ivunyiwe i-blinatumomab ukunyanga izigulane nge-chladosome ye-Philadelphia- umgcini-mgcawu we-B-cell acute lymphoblastic leukemia (B-cell ALL), ifomu engavamile YONKE.
Jonga uNicola Gokbuget, MD, uchaze indlela i-blinatumomab isebenza ngayo.
IiCAR eziPhambili kuzo zonke izixokelelwano
Idatha yexesha elide ukususela kwisilingo usebenzisa i-chimeric anti receptor (i-CAR) iiseli ze-T zibonisa ukuba la maseli ahlaziyiweyo anamathela ixesha elide, enza umsebenzi wawo, ekhokelela ekuhlehliseni ixesha elide. Abaninzi kuluntu lwenzululwazi banethemba ngoluhlobo oluthile lonyango kwiindidi ezahlukeneyo zeek Cancer ezingenakunzima ukuzenza.
Qaphela kwiZiphumo Zecala
Ingqalelo, zonke ezo zithunywa zinemiphumo emibi, ezinye zazo ezinokuthi zibe zikhulu, kwaye ezinye zazo zingaba zingaziwa. Njengawo onke amayeza, isigqibo sokwenza unyango sichaphazelwa yinto eyaziwayo malunga neengozi kunye neenzuzo zonyango kunye nezigulane zomntu ngamnye.
Imithombo
National Cancer Institute. Ulwazi lwesigulane seBlinatumomab. http://www.cancer.gov/drugdictionary?cdrid=487684. Ufikelele ngoDisemba 2014.
MedPageToday. http://www.medpagetoday.com/MeetingCoverage/ASHHematology/48998. Ufikelele ngoDisemba 2014.